Calliditas Therapeutics Investor Relations Material
Calliditas Therapeutics AB, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. Its lead product candidate is Nefecon that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy. Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden
Upcoming events for
Q2 20222022-08-18
Latest company events
Ticker symbol
CALTX
Country
Sweden
About the company
Investor Relations Page
Dig deeper into the Calliditas Therapeutics fundamentals on Quartr.
- Skip straight to the Q&A session
- Receive notifications about new events
- Connect the financial calender on your phone
- Figure out why the stock is up or down
- Read the transcripts or scroll the deck
- Access earnings or press releases
